Featured
-
-
News Explainer |
First cell therapy for solid tumours heads to the clinic: what it means for cancer treatment
Therapy built on tumour-infiltrating lymphocytes is now being prepared for at least 20 people in the United States with advanced melanoma.
- Sara Reardon
-
Correspondence |
Personalized cancer care can’t rely on molecular testing alone
- James Larkin
- , Chloe Beland
- & Alexander R. Lyon
-
Correspondence |
Forget lung, breast or prostate cancer? Why we shouldn’t abandon tumour names yet
- Albrecht Stenzinger
- & Frederick Klauschen
-
Spotlight |
Stealthy stem cells to treat disease
Gene-editing strategies that allow stem cells to evade the immune system offer hope for universal cell-replacement therapies.
- Elie Dolgin
-
Article
| Open AccessAn atlas of epithelial cell states and plasticity in lung adenocarcinoma
Analyses of single epithelial cells from early-stage lung adenocarcinoma and normal lung identifies a population of intermediate cells that may have an increased likelihood of transforming to tumour cells after injury such as tobacco exposure.
- Guangchun Han
- , Ansam Sinjab
- & Humam Kadara
-
Article |
SOX17 enables immune evasion of early colorectal adenomas and cancers
Transcriptomic and chromatin accessibility analyses of naive and transplanted colon cancer organoids in a mouse model reveal a key role for the transcription factor SOX17 in establishing a permissive immune environment for tumour cells.
- Norihiro Goto
- , Peter M. K. Westcott
- & Ömer H. Yilmaz
-
Article
| Open AccessAnti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
A high baseline of intratumoural macrophages and regulatory T cells is associated with better outcomes in patients with non-small cell lung cancer treated with atezolizumab plus tiragolumab, but not with atezolizumab alone.
- Xiangnan Guan
- , Ruozhen Hu
- & Namrata S. Patil
-
Obituary |
Judith Campisi (1948–2024), cell biologist who explored how cells age
Researcher who established the role of cellular senescence in cancer and ageing.
- Jan Vijg
- & Jan Hoeijmakers
-
News |
MEGA-CRISPR tool gives a power boost to cancer-fighting cells
A system that edits RNA rather than DNA can give new life to exhausted CAR T cells.
- Sara Reardon
-
Review Article |
Natural killer cell therapies
This Review explores in detail the complexity of NK cell biology in humans and highlights the role of these cells in cancer immunity.
- Eric Vivier
- , Lucas Rebuffet
- & Valeria R. Fantin
-
Article
| Open AccessMechanisms of action and resistance in histone methylation-targeted therapy
The mechanisms of action and resistance of valemetostat, an EZH1–EZH2 dual inhibitor, in patients with adult T cell leukaemia/lymphoma who initially responded but later showed disease progression are explored.
- Makoto Yamagishi
- , Yuta Kuze
- & Kaoru Uchimaru
-
Technology Feature |
Super-speedy sequencing puts genomic diagnosis in the fast lane
Streamlined workflows for DNA and RNA sequencing are helping clinicians to deliver prompt, targeted care to people in days — or even hours.
- Michael Eisenstein
-
News Feature |
The future of precision cancer therapy might be to try everything
Researchers are blasting patients’ cancer cells with dozens of drugs in the hope of finding the right treatment.
- Elie Dolgin
-
Article |
Deep whole-genome analysis of 494 hepatocellular carcinomas
The Chinese Liver Cancer Atlas project depicts a panoramic genomic landscape of hepatocellular carcinoma, covering candidate coding and non-coding drivers, mutational signatures, extrachromosomal circular DNA, subclonal catastrophic events and detailed evolutionary history.
- Lei Chen
- , Chong Zhang
- & Hongyang Wang
-
Article
| Open AccessGenetic determinants of micronucleus formation in vivo
Genetic screening identifies a rich catalogue of regulators of micronucleus formation.
- D. J. Adams
- , B. Barlas
- & G. Balmus
-
Nature Podcast |
Why we need to rethink how we talk about cancer
Naming metastatic cancers after parts of the body could be holding up research and preventing people from accessing the best treatment
- Lucy Odling-Smee
- & Noah Baker
-
News |
Turbocharged CAR-T cells melt tumours in mice — using a trick from cancer cells
Immune cells armed with a mutation first identified in cancer cells gain potency but don’t turn cancerous themselves.
- Asher Mullard
-
Article |
Naturally occurring T cell mutations enhance engineered T cell therapies
A study examines the effects of mutations that occur naturally in T cell cancers, reporting that such mutations can potentially be exploited to increase the potency of T cell therapies.
- Julie Garcia
- , Jay Daniels
- & Jaehyuk Choi
-
Article
| Open AccessThe nuclear factor ID3 endows macrophages with a potent anti-tumour activity
The Kupffer cell lineage-determining factor ID3 selectively endows macrophages with the ability to phagocytose live tumour cells and orchestrate the recruitment, proliferation and activation of natural killer and CD8+ T lymphoid effector cells to restrict the growth of a variety of tumours.
- Zihou Deng
- , Pierre-Louis Loyher
- & Frederic Geissmann
-
Nature Podcast |
Cancer’s power harnessed — lymphoma mutations supercharge T cells
Genetic changes that help tumour cells thrive can be co-opted to improve immunotherapy’s effectiveness, and looking at the electric vehicle batteries of the future.
- Benjamin Thompson
- & Nick Petrić Howe
-
Nature Podcast |
Cervical cancer could be eliminated: here’s how
Two experts lay out the steps that need to be taken, and the challenges facing low- and middle-income countries.
- Nick Petrić Howe
- & Jennifer Gardiner
-
Comment |
Forget lung, breast or prostate cancer: why tumour naming needs to change
The conventional way of classifying metastatic cancers according to their organ of origin is denying people access to drugs that could help them.
- Fabrice André
- , Elie Rassy
- & Benjamin Besse
-
News & Views |
Natural inhibitor found for cell death by ferroptosis
The discovery that an evolutionarily conserved molecule used to make cholesterol also acts as a defence against a cell-death mechanism called ferroptosis might lead to new ways to treat cancer and other clinical conditions.
- Donna D. Zhang
-
Article |
7-Dehydrocholesterol is an endogenous suppressor of ferroptosis
Proferroptotic activity of 7-dehydrocholesterol reductase is shown along with an unexpected prosurvival function of its substrate, 7-dehydrocholesterol, indicating a cell-intrinsic mechanism that could be used by cancer cells to protect phospholipids from oxidative damage and escape ferroptosis.
- Florencio Porto Freitas
- , Hamed Alborzinia
- & José Pedro Friedmann Angeli
-
Article
| Open AccessMatrix viscoelasticity promotes liver cancer progression in the pre-cirrhotic liver
Structural changes mediated by advanced glycation end-products enhance extracellular matrix viscoelasticity, and that viscoelasticity can promote cancer progression in vivo, independent of stiffness.
- Weiguo Fan
- , Kolade Adebowale
- & Natalie J. Török
-
Article |
7-Dehydrocholesterol dictates ferroptosis sensitivity
7-Dehydrocholesterol (7-DHC) is a natural anti-ferroptotic metabolite and pharmacological manipulation of 7-DHC levels shows promise as a therapeutic strategy for cancer and ischaemia–reperfusion injury.
- Yaxu Li
- , Qiao Ran
- & Ping Wang
-
Comment |
Cervical cancer kills 300,000 people a year — here’s how to speed up its elimination
Without rapid change, the World Health Organization’s goals for tackling cervical cancer by 2030 will be missed. Four experts share ways to move the needle.
- Lynette Denny
- , Ishu Kataria
- & Kathleen M. Schmeler
-
Research Highlight |
Engineered natural killer cells show their power against blood cancer
A variation on CAR T-cell therapy damps down the number of cancerous cells in people with certain types of lymphoma or leukaemia.
-
News & Views |
DNA sensing and repair systems unexpectedly team up against cancer
DNA in the cytoplasm can be a sign of abnormalities such as viral infections or cancer. A protein with a role in DNA-damage response was unexpectedly found to activate defences against the threats indicated by cytoplasmic DNA.
- Silvia Monticelli
- & Petr Cejka
-
Article
| Open AccessMRE11 liberates cGAS from nucleosome sequestration during tumorigenesis
The double-strand break sensor MRE11 is identified as a pivotal mediator of cGAS activation in response to multiple types of DNA damage.
- Min-Guk Cho
- , Rashmi J. Kumar
- & Gaorav P. Gupta
-
News |
Scientists question cancer tests that use microscopic nematode worms
Some doctors say a troublingly high number of cancer-free people have tested positive on the tests sold by a Japanese start-up.
- David McNeill
- & Momoko Suda
-
News Feature |
Nature’s 10: ten people (and one non-human) who helped shape science in 2023
An AI pioneer, an architect of India’s Moon mission and the world’s first global heat officer are some of the people behind this year’s big stories.
-
News Feature |
The cancer physician who helped to deliver a life-extending treatment
Thomas Powles’s breakthrough success in treating a deadly bladder cancer could herald the next wave of powerful immunotherapeutic drugs.
- Carissa Wong
-
Article |
Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides
The tumour-specific circular RNA FAM53B is highly immunogenic and can induce anti-tumour responses in mouse models of breast cancer and melanoma, expanding the repertoire of anticancer targets for development.
- Di Huang
- , Xiaofeng Zhu
- & Erwei Song
-
News & Views |
MYC protein helps cancer to take its vitamins
Identifying nutrient dependencies of cancer cells is crucial for developing new therapies. The discovery that an aggressive type of cancer cell has a high uptake of vitamin B5 sheds light on the link between vitamin availability and tumour growth.
- Martina Wallace
-
Article |
Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling
The potential use of circulating tumour DNA in classic Hodgkin lymphoma detection, classification and monitoring is defined.
- Stefan K. Alig
- , Mohammad Shahrokh Esfahani
- & Ash A. Alizadeh
-
News & Views |
Harmful tumour–kidney interactions identified
Fatal renal dysfunction is often associated with tumour development. Fly and mouse data reveal evolutionarily conserved mechanisms that link tumours to renal failure and offer potential for future therapeutic approaches.
- Pierre Leopold
-
News & Views |
15 years after a giant leap for cancer genomics
In 2008, the first comprehensive sequence of a cancer genome was reported, ushering in a new era of molecular diagnostic, prognostic and therapeutic advances informed by an essential framework to understand cancer’s complexities.
- Sheng F. Cai
- & Ross L. Levine
-
Article
| Open AccessTrans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity
A screen of nutrient-derived compounds identified trans-vaccenic acid as a promoter of effector T cell function, and functional assays demonstrate that this occurs via inactivation of GPR43 on T cells.
- Hao Fan
- , Siyuan Xia
- & Jing Chen
-
Article |
The extracellular matrix dictates regional competence for tumour initiation
Experiments in mice show that expression of the oncogene SmoM2 induces basal cell carcinoma in the ear epidermis but not in the back skin, and that this difference in susceptibility is regulated by the extracellular matrix.
- Nordin Bansaccal
- , Pauline Vieugue
- & Cédric Blanpain
-
Article |
Stepwise requirements for polymerases δ and θ in theta-mediated end joining
Polymerase delta is required for multiple steps in polymerase theta-dependent repair of chromosome breaks, a pathway targeted in cancer therapy.
- Susanna Stroik
- , Juan Carvajal-Garcia
- & Dale A. Ramsden
-
Article
| Open AccessTargeting of intracellular oncoproteins with peptide-centric CARs
Peptide-centric chimeric antigen receptors (PC-CARs) provide a platform to address the challenges involved in targeting intracellular oncoproteins, and PC-CARs based on the neuroblastoma-dependency gene PHOX2B induce elimination of aggressive tumors.
- Mark Yarmarkovich
- , Quinlen F. Marshall
- & John M. Maris
-
Article |
Latent human herpesvirus 6 is reactivated in CAR T cells
Genomics analyses reveal that in vitro culture of CAR T cells can lead to reactivation of a latent herpesvirus, which might be involved in complications in patients receiving associated cell therapies.
- Caleb A. Lareau
- , Yajie Yin
- & Ansuman T. Satpathy
-
News & Views |
Brain cancer thrives by hijacking mechanisms to boost synapse strength
Synaptic connections between cancer cells and neurons can boost tumour growth. Analyses of brain tumours reveal how cancer cells enhance the strength of synapses with neurons to promote tumour survival.
- Matthew B. Dalva
-
News |
Cancer trial results show power of weaponized antibodies
Tumour-targeting antibodies coupled with toxic chemicals are an unprecedented success in treating bladder cancer.
- Heidi Ledford
-
Article |
IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer
Single-cell and spatial gene expression analyses of pancreatic ductal adenocarcinoma uncover a population of interleukin-1β-expressing macrophages that drive inflammatory reprogramming of neighboring tumour cells leading to disease progression and poor prognosis for patients.
- Nicoletta Caronni
- , Federica La Terza
- & Renato Ostuni
-
Article
| Open AccessEpigenetic regulation during cancer transitions across 11 tumour types
A pan-cancer epigenetic and transcriptomic atlas identifies epigenetic drivers associated with cancer transitions.
- Nadezhda V. Terekhanova
- , Alla Karpova
- & Li Ding
-
Article
| Open AccessGlioma synapses recruit mechanisms of adaptive plasticity
In glioma, malignant synapses hijack mechanisms of synaptic plasticity to increase glutamate-dependent currents in tumour cells and the formation of neuron–glioma synapses, thereby promoting tumour proliferation and progression.
- Kathryn R. Taylor
- , Tara Barron
- & Michelle Monje
-
Article |
Disruption of sugar nucleotide clearance is a therapeutic vulnerability of cancer cells
An enzyme called UXS1 that converts one sugar nucleotide to another is needed more in some cancer cells than in normal cells, providing a potential weakness that can be exploited therapeutically.
- Mihir B. Doshi
- , Namgyu Lee
- & Dohoon Kim
Browse broader subjects
Browse narrower subjects
- Bone cancer
- Breast cancer
- Cancer epidemiology
- Cancer genetics
- Cancer genomics
- Cancer imaging
- Cancer metabolism
- Cancer microenvironment
- Cancer models
- Cancer of unknown primary
- Cancer prevention
- Cancer screening
- Cancer stem cells
- Cancer therapy
- CNS cancer
- Cysts
- Embryonal neoplasms
- Endocrine cancer
- Eye cancer
- Gastrointestinal cancer
- Germ cell tumours
- Gynaecological cancer
- Haematological cancer
- Hamartoma
- Head and neck cancer
- Lung cancer
- Mesothelioma
- Metastasis
- Oncogenes
- Oral cancer
- Paediatric cancer
- Sarcoma
- Skin cancer
- Testicular cancer
- Tumour angiogenesis
- Tumour biomarkers
- Tumour heterogeneity
- Tumour immunology
- Tumour-suppressor proteins
- Tumour virus infections
- Urological cancer